AR108717A1 - Anticuerpos antifactor de la coagulación xi - Google Patents
Anticuerpos antifactor de la coagulación xiInfo
- Publication number
- AR108717A1 AR108717A1 ARP170101603A ARP170101603A AR108717A1 AR 108717 A1 AR108717 A1 AR 108717A1 AR P170101603 A ARP170101603 A AR P170101603A AR P170101603 A ARP170101603 A AR P170101603A AR 108717 A1 AR108717 A1 AR 108717A1
- Authority
- AR
- Argentina
- Prior art keywords
- afxi
- family
- variable region
- seq
- amino acid
- Prior art date
Links
- 230000015271 coagulation Effects 0.000 title 1
- 238000005345 coagulation Methods 0.000 title 1
- 208000024178 Acquired factor XI deficiency Diseases 0.000 abstract 9
- 125000003275 alpha amino acid group Chemical group 0.000 abstract 6
- 108010047041 Complementarity Determining Regions Proteins 0.000 abstract 4
- 101710161089 Coagulation factor XI Proteins 0.000 abstract 2
- 102100030563 Coagulation factor XI Human genes 0.000 abstract 2
- 230000004913 activation Effects 0.000 abstract 2
- 108010071241 Factor XIIa Proteins 0.000 abstract 1
- 101001062768 Homo sapiens Coagulation factor XI Proteins 0.000 abstract 1
- 238000007792 addition Methods 0.000 abstract 1
- 150000001413 amino acids Chemical class 0.000 abstract 1
- 239000000427 antigen Substances 0.000 abstract 1
- 102000036639 antigens Human genes 0.000 abstract 1
- 108091007433 antigens Proteins 0.000 abstract 1
- 230000037430 deletion Effects 0.000 abstract 1
- 238000012217 deletion Methods 0.000 abstract 1
- 239000012634 fragment Substances 0.000 abstract 1
- 238000006467 substitution reaction Methods 0.000 abstract 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/36—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against blood coagulation factors
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
- A61K39/39533—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals
- A61K39/3955—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals against proteinaceous materials, e.g. enzymes, hormones, lymphokines
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P7/00—Drugs for disorders of the blood or the extracellular fluid
- A61P7/02—Antithrombotic agents; Anticoagulants; Platelet aggregation inhibitors
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/58—Medicinal preparations containing antigens or antibodies raising an immune response against a target which is not the antigen used for immunisation
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
- C07K2317/52—Constant or Fc region; Isotype
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
- C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
- C07K2317/565—Complementarity determining region [CDR]
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
- C07K2317/75—Agonist effect on antigen
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
- C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
- C07K2317/92—Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Medicinal Chemistry (AREA)
- Organic Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Immunology (AREA)
- Hematology (AREA)
- Public Health (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Pharmacology & Pharmacy (AREA)
- Veterinary Medicine (AREA)
- Animal Behavior & Ethology (AREA)
- Engineering & Computer Science (AREA)
- Molecular Biology (AREA)
- Biophysics (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Genetics & Genomics (AREA)
- Biochemistry (AREA)
- Mycology (AREA)
- Microbiology (AREA)
- Epidemiology (AREA)
- Endocrinology (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Diabetes (AREA)
- Peptides Or Proteins (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
- Preparation Of Compounds By Using Micro-Organisms (AREA)
- Management, Administration, Business Operations System, And Electronic Commerce (AREA)
Abstract
Se describen anticuerpos que se unen al dominio apple 3 del factor de la coagulación humano XI e inhiben la activación del FXI por el factor de la coagulación XIIa, así como la activación del FXI por el FXa. Reivindicación 1: Un anticuerpo o fragmento de unión al antígeno que comprende: (i) al menos las seis regiones determinantes de la complementariedad (CDR) de un anticuerpo anti-FXI de la familia aFXI-18623p, la familia aFXI-18611p, o la familia aFXI-18611 o (ii) al menos las seis regiones determinantes de la complementariedad (CDR) de un anticuerpo anti-FXI de la familia aFXI-18623p, la familia aFXI-18611p, o la familia aFXI-18611 en la que una o más de las seis CDR tienen una, dos o tres sustituciones, adiciones o deleciones de aminoácidos, o combinaciones de las mismas, en el que un anticuerpo de la familia aFXI-18623 comprende una región variable de cadena pesada (HC) que tiene la secuencia de aminoácidos mostrada en SEQ ID Nº 28 ó 29 y una región variable y una región variable de cadena ligera (LC) que tiene la secuencia de aminoácidos mostrada en SEQ ID Nº 30; un anticuerpo de la familia aFXI-18611p comprende una región variable de HC que tiene la secuencia de aminoácidos mostrada en SEQ ID Nº 21 ó 22 y una región variable de cadena ligera (LC) que tiene la secuencia de aminoácidos mostrada en SEQ ID Nº 25; y un anticuerpo de la familia aFXI-18611 comprende una región variable de HC que tiene la secuencia de aminoácidos mostrada en SEQ ID Nº 23 ó 24 y una región variable de LC que tiene la secuencia de aminoácidos mostrada en SEQ ID Nº 25.
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201662349888P | 2016-06-14 | 2016-06-14 |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| AR108717A1 true AR108717A1 (es) | 2018-09-19 |
Family
ID=59078269
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| ARP170101603A AR108717A1 (es) | 2016-06-14 | 2017-06-12 | Anticuerpos antifactor de la coagulación xi |
Country Status (28)
| Country | Link |
|---|---|
| US (6) | US10676536B2 (es) |
| EP (1) | EP3469002A1 (es) |
| JP (2) | JP7022081B2 (es) |
| KR (2) | KR102218714B1 (es) |
| CN (2) | CN109476758B (es) |
| AR (1) | AR108717A1 (es) |
| AU (3) | AU2017286432B2 (es) |
| BR (1) | BR112018075858A2 (es) |
| CA (2) | CA3025869A1 (es) |
| CL (2) | CL2018003565A1 (es) |
| CO (1) | CO2018013434A2 (es) |
| CR (1) | CR20180583A (es) |
| DO (1) | DOP2018000284A (es) |
| EA (1) | EA201892716A1 (es) |
| EC (1) | ECSP18091593A (es) |
| GE (1) | GEP20227382B (es) |
| IL (2) | IL315266A (es) |
| JO (1) | JOP20180121A1 (es) |
| MA (1) | MA45234A (es) |
| MX (2) | MX2018015757A (es) |
| MY (1) | MY201852A (es) |
| NI (1) | NI201800134A (es) |
| PE (1) | PE20190416A1 (es) |
| PH (1) | PH12018502586A1 (es) |
| SG (2) | SG11201810763TA (es) |
| TN (1) | TN2018000417A1 (es) |
| TW (2) | TWI752964B (es) |
| WO (1) | WO2017218371A1 (es) |
Families Citing this family (10)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JOP20200312A1 (ar) | 2015-06-26 | 2017-06-16 | Novartis Ag | الأجسام المضادة للعامل xi وطرق الاستخدام |
| TW201802121A (zh) | 2016-05-25 | 2018-01-16 | 諾華公司 | 抗因子XI/XIa抗體之逆轉結合劑及其用途 |
| CA3025869A1 (en) * | 2016-06-14 | 2017-12-21 | Merck Sharp & Dohme Corp. | Anti-coagulation factor xi antibodies |
| IL308980A (en) | 2016-12-23 | 2024-01-01 | Novartis Ag | Antibodies against factor XI and methods of their use |
| CN110423278B (zh) * | 2019-08-08 | 2020-07-17 | 上海博槿生物科技有限公司 | 一种抗凝血因子XI活化形式因子XIa的抗体及其制备方法和应用 |
| CA3184718A1 (en) * | 2020-07-02 | 2022-01-06 | Lei Wang | Anti-fxi/fxia antibody, antigen-binding fragment thereof, and pharmaceutical use thereof |
| AU2021302199A1 (en) * | 2020-07-03 | 2023-02-23 | Suzhou Alphamab Co., Ltd. | Coagulation factor XI (FXI) binding protein |
| EP4291579A1 (en) * | 2021-02-09 | 2023-12-20 | Arxx Therapeutics AS | Anti-s100a4 humanized antibodies, uses and methods |
| WO2023098637A1 (zh) * | 2021-11-30 | 2023-06-08 | 苏州康宁杰瑞生物科技有限公司 | 预防和/或治疗血栓栓塞性疾病的方法 |
| WO2024141099A1 (zh) * | 2022-12-30 | 2024-07-04 | 甘李药业股份有限公司 | 抗凝血因子XI和/或其活化形式因子XIa的抗体及其用途 |
Family Cites Families (91)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US4447233A (en) | 1981-04-10 | 1984-05-08 | Parker-Hannifin Corporation | Medication infusion pump |
| US4439196A (en) | 1982-03-18 | 1984-03-27 | Merck & Co., Inc. | Osmotic drug delivery system |
| US4447224A (en) | 1982-09-20 | 1984-05-08 | Infusaid Corporation | Variable flow implantable infusion apparatus |
| US4487603A (en) | 1982-11-26 | 1984-12-11 | Cordis Corporation | Implantable microinfusion pump system |
| US4816567A (en) | 1983-04-08 | 1989-03-28 | Genentech, Inc. | Recombinant immunoglobin preparations |
| US4596556A (en) | 1985-03-25 | 1986-06-24 | Bioject, Inc. | Hypodermic injection apparatus |
| US4941880A (en) | 1987-06-19 | 1990-07-17 | Bioject, Inc. | Pre-filled ampule and non-invasive hypodermic injection device assembly |
| US4790824A (en) | 1987-06-19 | 1988-12-13 | Bioject, Inc. | Non-invasive hypodermic injection device |
| DE68919361T2 (de) | 1988-06-21 | 1995-05-24 | Genentech Inc | Therapeutische zusammensetzungen für die behandlung von myocard-infarkten. |
| US5530101A (en) * | 1988-12-28 | 1996-06-25 | Protein Design Labs, Inc. | Humanized immunoglobulins |
| DE3920358A1 (de) | 1989-06-22 | 1991-01-17 | Behringwerke Ag | Bispezifische und oligospezifische, mono- und oligovalente antikoerperkonstrukte, ihre herstellung und verwendung |
| US5064413A (en) | 1989-11-09 | 1991-11-12 | Bioject, Inc. | Needleless hypodermic injection device |
| US5312335A (en) | 1989-11-09 | 1994-05-17 | Bioject Inc. | Needleless hypodermic injection device |
| US5545806A (en) | 1990-08-29 | 1996-08-13 | Genpharm International, Inc. | Ransgenic non-human animals for producing heterologous antibodies |
| US5661016A (en) | 1990-08-29 | 1997-08-26 | Genpharm International Inc. | Transgenic non-human animals capable of producing heterologous antibodies of various isotypes |
| US5770429A (en) | 1990-08-29 | 1998-06-23 | Genpharm International, Inc. | Transgenic non-human animals capable of producing heterologous antibodies |
| US5874299A (en) | 1990-08-29 | 1999-02-23 | Genpharm International, Inc. | Transgenic non-human animals capable of producing heterologous antibodies |
| ATE158021T1 (de) | 1990-08-29 | 1997-09-15 | Genpharm Int | Produktion und nützung nicht-menschliche transgentiere zur produktion heterologe antikörper |
| US5625126A (en) | 1990-08-29 | 1997-04-29 | Genpharm International, Inc. | Transgenic non-human animals for producing heterologous antibodies |
| US5633425A (en) | 1990-08-29 | 1997-05-27 | Genpharm International, Inc. | Transgenic non-human animals capable of producing heterologous antibodies |
| US5814318A (en) | 1990-08-29 | 1998-09-29 | Genpharm International Inc. | Transgenic non-human animals for producing heterologous antibodies |
| US5789650A (en) | 1990-08-29 | 1998-08-04 | Genpharm International, Inc. | Transgenic non-human animals for producing heterologous antibodies |
| US5877397A (en) | 1990-08-29 | 1999-03-02 | Genpharm International Inc. | Transgenic non-human animals capable of producing heterologous antibodies of various isotypes |
| EP0617706B1 (en) | 1991-11-25 | 2001-10-17 | Enzon, Inc. | Multivalent antigen-binding proteins |
| US5383851A (en) | 1992-07-24 | 1995-01-24 | Bioject Inc. | Needleless hypodermic injection device |
| JPH0656382A (ja) | 1992-08-04 | 1994-03-01 | Kawasaki Steel Corp | コークス乾式消火装置のバケット巻上機の吊ビーム装置 |
| MA24512A1 (fr) | 1996-01-17 | 1998-12-31 | Univ Vermont And State Agrienl | Procede pour la preparation d'agents anticoagulants utiles dans le traitement de la thrombose |
| GB9818110D0 (en) | 1998-08-19 | 1998-10-14 | Weston Medical Ltd | Needleless injectors and other devices |
| US6096002A (en) | 1998-11-18 | 2000-08-01 | Bioject, Inc. | NGAS powered self-resetting needle-less hypodermic jet injection apparatus and method |
| AU764211C (en) | 1998-12-01 | 2006-03-30 | Abbvie Biotherapeutics Inc. | Humanized antibodies to gamma-interferon |
| JP5198704B2 (ja) | 2000-03-03 | 2013-05-15 | メディミューン リミティド | エオタキシンに対するヒト抗体及びそれらの使用 |
| KR100708398B1 (ko) | 2002-03-22 | 2007-04-18 | (주) 에이프로젠 | 인간화 항체 및 이의 제조방법 |
| GEP20196963B (en) | 2003-07-15 | 2019-04-10 | Inc Amgen | Human anti-ngf neutralizing antibodies as selective ngf pathway inhibitors |
| SG158150A1 (en) | 2004-12-21 | 2010-01-29 | Centocor Inc | Anti-il-12 antibodies, epitopes, compositions, methods and uses |
| US8318906B2 (en) | 2005-04-15 | 2012-11-27 | The Regents Of The University Of California | EMP2 antibodies and their therapeutic uses |
| NZ563193A (en) | 2005-05-09 | 2010-05-28 | Ono Pharmaceutical Co | Human monoclonal antibodies to programmed death 1(PD-1) and methods for treating cancer using anti-PD-1 antibodies alone or in combination with other immunotherapeutics |
| DK1907424T3 (en) | 2005-07-01 | 2015-11-09 | Squibb & Sons Llc | HUMAN MONOCLONAL ANTIBODIES TO PROGRAMMED death ligand 1 (PD-L1) |
| ES2390476T3 (es) | 2005-12-08 | 2012-11-13 | Medarex, Inc. | Anticuerpos monoclonales frente a fucosil-GM1 y procedimientos de uso de anti-fucosil-GM1 |
| KR101373464B1 (ko) | 2005-12-08 | 2014-03-14 | 메다렉스, 엘.엘.시. | 단백질 티로신 키나제 7(ｐｔｋ7)에 대한 인간 단일클론항체 및 그의 용도 |
| JP5586952B2 (ja) | 2006-06-06 | 2014-09-10 | クルセル ホランド ベー ヴェー | 腸球菌に対する殺活性を有するヒトの結合分子及びその使用方法 |
| BRPI0715141A2 (pt) * | 2006-08-03 | 2013-06-04 | Astrazeneca Ab | agente de ligaÇço alvejante, anticorpo isolado, fragmento de anticorpo isolado, molÉcula de Ácido nucleico, vetor, cÉlula hospedeira, mÉtodos para produzir um agente de ligaÇço alvejado, para produzir um anticorpo, para produzir um fragmento de anticorpo, para tratar um tumor maligno em um animal, para tratar inflamaÇço, e para inibir a interaÇço de alfabeta6 com seu ligando, e, conjugado |
| CL2007002567A1 (es) | 2006-09-08 | 2008-02-01 | Amgen Inc | Proteinas aisladas de enlace a activina a humana. |
| US7833527B2 (en) | 2006-10-02 | 2010-11-16 | Amgen Inc. | Methods of treating psoriasis using IL-17 Receptor A antibodies |
| US8598321B2 (en) | 2007-03-22 | 2013-12-03 | The Regents Of The University Of California | Therapeutic monoclonal antibodies that neutralize botulinum neurotoxins |
| GB0708585D0 (en) | 2007-05-03 | 2007-06-13 | Queen Mary & Westfield College | Novel antibody and use in diagnosis and therapy of arthropathies |
| US7982016B2 (en) | 2007-09-10 | 2011-07-19 | Amgen Inc. | Antigen binding proteins capable of binding thymic stromal lymphopoietin |
| US8877688B2 (en) | 2007-09-14 | 2014-11-04 | Adimab, Llc | Rationally designed, synthetic antibody libraries and uses therefor |
| BRPI0816785A2 (pt) | 2007-09-14 | 2017-05-02 | Adimab Inc | bibliotecas de anticorpos sintéticos racionalmente desenhadas, e, usos para as mesmas |
| SG187477A1 (en) | 2007-09-26 | 2013-02-28 | U3 Pharma Gmbh | Heparin-binding epidermal growth factor-like growth factor antigen binding proteins |
| PT3002298T (pt) * | 2007-11-21 | 2019-11-20 | Univ Oregon Health & Science | Anticorpos monoclonais anti-fator xi e métodos de utilização dos mesmos |
| US8188235B2 (en) | 2008-06-18 | 2012-05-29 | Pfizer Inc. | Antibodies to IL-6 and their uses |
| WO2009154461A1 (en) | 2008-06-19 | 2009-12-23 | Prothix Bv | Use of anti-factors xi antibodies for prevention of thrombus formation |
| CA2732003A1 (en) | 2008-07-31 | 2010-02-04 | James D. Marks | Antibodies that neutralize botulinum neurotoxins |
| KR101683033B1 (ko) | 2008-10-31 | 2016-12-06 | 얀센 바이오테크 인코포레이티드 | 톨-유사 수용체 3 길항제 |
| EP2356270B1 (en) * | 2008-11-07 | 2016-08-24 | Fabrus Llc | Combinatorial antibody libraries and uses thereof |
| US9452227B2 (en) | 2008-11-25 | 2016-09-27 | Alderbio Holdings Llc | Methods of treating or diagnosing conditions associated with elevated IL-6 using anti-IL-6 antibodies or fragments |
| US9212223B2 (en) | 2008-11-25 | 2015-12-15 | Alderbio Holdings Llc | Antagonists of IL-6 to prevent or treat thrombosis |
| US8388959B2 (en) | 2008-12-18 | 2013-03-05 | Oregon Health & Science University | Anti-fXI antibodies and methods of use |
| US20120114667A1 (en) * | 2008-12-23 | 2012-05-10 | Medimmune Limited | TARGETED BINDING AGENTS DIRECTED TO a5BETA1 AND USES THEREOF |
| MX2011009798A (es) | 2009-03-20 | 2011-12-08 | Amgen Inc | Inmunoglobulinas portadoras y usos de las mismas. |
| RU2595379C2 (ru) | 2009-04-16 | 2016-08-27 | АббВай Биотерапеутикс Инк. | АНТИТЕЛА ПРОТИВ TNF-α И ИХ ПРИМЕНЕНИЯ |
| PL2426148T3 (pl) | 2009-04-27 | 2016-01-29 | Kyowa Hakko Kirin Co Ltd | Przeciwciało anty-IL-3RA do stosowania w leczeniu nowotworu krwi |
| BR112012008665A2 (pt) | 2009-10-12 | 2016-11-22 | Pfizer | tratamento de câncer |
| JP6007420B2 (ja) * | 2009-11-04 | 2016-10-12 | ファブラス エルエルシー | 親和性成熟に基づく抗体最適化方法 |
| WO2011079004A1 (en) | 2009-12-23 | 2011-06-30 | Schering Corporation | Cell line 3m |
| US20110244826A1 (en) * | 2010-02-03 | 2011-10-06 | Subramaniyan Krishnan | Mobile communication plan offerings |
| KR102024922B1 (ko) | 2010-07-16 | 2019-09-25 | 아디맵 엘엘씨 | 항체 라이브러리 |
| CA2815154A1 (en) * | 2010-08-06 | 2012-02-09 | U3 Pharma Gmbh | Use of her3 binding agents in prostate treatment |
| PE20140633A1 (es) | 2010-11-19 | 2014-05-30 | Eisai Randd Man Co Ltd | Anticuerpos neutralizadores anti-ccl20 |
| KR102320178B1 (ko) | 2011-01-06 | 2021-11-02 | 다케다 파머수티컬 컴패니 리미티드 | 혈장 칼리크레인 결합 단백질 |
| MY160662A (en) | 2011-04-01 | 2017-03-15 | Memorial Sloan Kettering Cancer Center | T cell receptor-like antibodies specific for a wt1 peptide presented by hla-a2 |
| ES2693647T3 (es) | 2011-06-06 | 2018-12-13 | Novo Nordisk A/S | Anticuerpos terapéuticos |
| US8765385B2 (en) | 2011-10-27 | 2014-07-01 | Ravindra Kumar | Method of detection of neutralizing anti-actriib antibodies |
| EP2650310B1 (en) | 2012-04-13 | 2016-06-08 | Rottapharm Biotech S.r.l. | Anti-ADAMTS-5 antibody, derivatives and uses thereof |
| CN104684932B (zh) | 2012-05-10 | 2019-03-12 | 拜耳药业股份公司 | 能够结合凝血因子XI和/或其活化形式因子XIa的抗体及其用途 |
| US9944707B2 (en) | 2012-05-17 | 2018-04-17 | Sorrento Therapeutics, Inc. | Antibodies that bind epidermal growth factor receptor (EGFR) |
| WO2014004549A2 (en) | 2012-06-27 | 2014-01-03 | Amgen Inc. | Anti-mesothelin binding proteins |
| US9498532B2 (en) | 2013-03-13 | 2016-11-22 | Novartis Ag | Antibody drug conjugates |
| CA2925057A1 (en) * | 2013-10-01 | 2015-04-09 | Simon T. BARRY | Methods of treating and diagnosing alpha-v-beta-6 overexpressing cancer |
| BR112016021576A2 (pt) | 2014-03-20 | 2017-10-10 | Japan As Represented By Director General Of Nat Institute Of Infectious Diseases | ?anticorpo da proteína e2 de vírus anti-hepatite c ou fragmento do anticorpo que se liga ao antígeno da mesma, ácido nucleico, e, medicamento? |
| NZ726911A (en) | 2014-06-03 | 2023-01-27 | Xbiotech Inc | Compositions and methods for treating and preventing staphylococcus aureus infections |
| CN107106679B (zh) | 2014-08-08 | 2022-07-26 | 艾利妥 | 抗trem2抗体及其使用方法 |
| US9139653B1 (en) | 2015-04-30 | 2015-09-22 | Kymab Limited | Anti-human OX40L antibodies and methods of treatment |
| WO2016164637A1 (en) | 2015-04-07 | 2016-10-13 | Alector Llc | Anti-sortilin antibodies and methods of use thereof |
| JP7497953B2 (ja) | 2015-06-12 | 2024-06-11 | アレクトル エルエルシー | 抗ｃｄ３３抗体及びその使用方法 |
| JOP20200312A1 (ar) | 2015-06-26 | 2017-06-16 | Novartis Ag | الأجسام المضادة للعامل xi وطرق الاستخدام |
| US11066481B2 (en) | 2015-07-23 | 2021-07-20 | The Regents Of The University Of California | Antibodies to coagulation factor XIa and uses thereof |
| EP3356415B1 (en) | 2015-09-29 | 2024-05-01 | Amgen Inc. | Asgr inhibitors for reduzing cholesterol levels |
| WO2017127468A1 (en) | 2016-01-22 | 2017-07-27 | Merck Sharp & Dohme Corp. | Anti-coagulation factor xi antibodies |
| CA3025869A1 (en) * | 2016-06-14 | 2017-12-21 | Merck Sharp & Dohme Corp. | Anti-coagulation factor xi antibodies |
| PE20191319A1 (es) | 2016-09-20 | 2019-09-24 | Bayer Pharma AG | Anticuerpos novedosos contra el factor xi y sus usos |
-
2017
- 2017-06-12 CA CA3025869A patent/CA3025869A1/en active Pending
- 2017-06-12 SG SG11201810763TA patent/SG11201810763TA/en unknown
- 2017-06-12 CN CN201780037421.3A patent/CN109476758B/zh active Active
- 2017-06-12 US US15/619,620 patent/US10676536B2/en active Active
- 2017-06-12 GE GEAP201714983A patent/GEP20227382B/en unknown
- 2017-06-12 IL IL315266A patent/IL315266A/en unknown
- 2017-06-12 JP JP2018565042A patent/JP7022081B2/ja active Active
- 2017-06-12 WO PCT/US2017/036940 patent/WO2017218371A1/en unknown
- 2017-06-12 MA MA045234A patent/MA45234A/fr unknown
- 2017-06-12 MY MYPI2018002406A patent/MY201852A/en unknown
- 2017-06-12 PE PE2018003203A patent/PE20190416A1/es unknown
- 2017-06-12 TW TW106119391A patent/TWI752964B/zh active
- 2017-06-12 MX MX2018015757A patent/MX2018015757A/es unknown
- 2017-06-12 EP EP17731444.0A patent/EP3469002A1/en active Pending
- 2017-06-12 CR CR20180583A patent/CR20180583A/es unknown
- 2017-06-12 KR KR1020197001266A patent/KR102218714B1/ko active IP Right Grant
- 2017-06-12 TW TW110149482A patent/TWI802193B/zh active
- 2017-06-12 CN CN202310501882.9A patent/CN116425879A/zh active Pending
- 2017-06-12 EA EA201892716A patent/EA201892716A1/ru unknown
- 2017-06-12 AR ARP170101603A patent/AR108717A1/es unknown
- 2017-06-12 BR BR112018075858-2A patent/BR112018075858A2/pt unknown
- 2017-06-12 TN TNP/2018/000417A patent/TN2018000417A1/en unknown
- 2017-06-12 KR KR1020217004608A patent/KR102379580B1/ko active IP Right Grant
- 2017-06-12 AU AU2017286432A patent/AU2017286432B2/en active Active
- 2017-06-12 CA CA3172367A patent/CA3172367A1/en active Pending
- 2017-06-12 SG SG10202103120UA patent/SG10202103120UA/en unknown
- 2017-06-16 JO JOP/2018/0121A patent/JOP20180121A1/ar unknown
-
2018
- 2018-11-25 IL IL263272A patent/IL263272A/en unknown
- 2018-12-06 PH PH12018502586A patent/PH12018502586A1/en unknown
- 2018-12-10 NI NI201800134A patent/NI201800134A/es unknown
- 2018-12-11 CL CL2018003565A patent/CL2018003565A1/es unknown
- 2018-12-11 EC ECSENADI201891593A patent/ECSP18091593A/es unknown
- 2018-12-12 CO CONC2018/0013434A patent/CO2018013434A2/es unknown
- 2018-12-13 DO DO2018000284A patent/DOP2018000284A/es unknown
- 2018-12-14 MX MX2023012740A patent/MX2023012740A/es unknown
-
2020
- 2020-05-01 US US16/864,559 patent/US11661460B2/en active Active
- 2020-05-01 US US16/864,583 patent/US11479615B2/en active Active
- 2020-05-01 US US16/864,570 patent/US11512142B2/en active Active
- 2020-05-01 US US16/864,577 patent/US11485794B2/en active Active
- 2020-07-30 AU AU2020210233A patent/AU2020210233B2/en active Active
-
2021
- 2021-03-26 JP JP2021053470A patent/JP7277500B2/ja active Active
-
2023
- 2023-04-18 US US18/302,033 patent/US20230287141A1/en active Pending
-
2024
- 2024-02-06 CL CL2024000367A patent/CL2024000367A1/es unknown
- 2024-02-20 AU AU2024201084A patent/AU2024201084A1/en active Pending
Also Published As
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| AR108717A1 (es) | Anticuerpos antifactor de la coagulación xi | |
| UY36194A (es) | Anticuerpos anti-tau humanizados | |
| CY1124691T1 (el) | Διειδικα αντισωματα ειδικα για pd1 και τιμ3 | |
| CU24568B1 (es) | Anticuerpo inhibidor de masp-3 | |
| CY1120414T1 (el) | Αντισωματα που συνδεονται me οχ40 και οι χρησεις τους | |
| AR104280A1 (es) | Terapia de combinación con factores de coagulación y anticuerpos multiespecíficos | |
| AR106184A1 (es) | Proteínas de unión a pd-1 y sus métodos de uso | |
| UY37694A (es) | Dominios de unión a antígeno humanizados y métodos de uso | |
| EA201791961A1 (ru) | Антитела, специфичные к cd47 и pd-l1 | |
| EA201992091A1 (ru) | Анти-c5 антитела и их применение | |
| EA201692394A1 (ru) | Антитела и антигенсвязывающие фрагменты, которые специфично связываются с белком тау, ассоциированным с микротрубочками | |
| AR107505A1 (es) | Anticuerpos anti-factor de la coagulación xi | |
| PE20161390A1 (es) | Anticuerpos multiespecificos | |
| CL2016000324A1 (es) | Anticuerpos monoclonales que se unen especificamente al inhibidor del activador de plasminogeno de tipo 1 (pai-1); y uso para preparar un medicamento util para restaurar la generación de plasmina o tratar una afeccion causada por el aumento de los niveles de pai-1 o el aumento de la sensibilidad a pai-1. | |
| ES2687282T3 (es) | Anticuerpos humanizados ANTI-CD134 (OX40) y sus usos | |
| AR105267A1 (es) | Anticuerpos de unión a tau | |
| CO2017010316A2 (es) | Anticuerpo monoclonal aislado y / o recombinante y un método para identificar la infección por el virus de chikungunya glycoprotein e2 mediante el contacto con una muestra con un anticuerpo o fragmento de anticuerpos con secuencias cdr de cadena pesada y ligera | |
| EA201791527A1 (ru) | Биспецифические антитела против плазменного калликреина и фактора xii | |
| PE20151289A1 (es) | Anticuerpos que se unen al tl1a y sus usos | |
| EA201491599A1 (ru) | Антитела к матриксной металлопротеиназе 9 | |
| CO2018000652A2 (es) | Anticuerpo anti-epha4 | |
| EA201992206A1 (ru) | Моноклональное антитело к pd-l1 | |
| CO2020013833A2 (es) | Anticuerpo anti-muerte programada-ligando 1 y su uso | |
| EA201992248A1 (ru) | АНТИ-C5a-АНТИТЕЛА И ИХ ПРИМЕНЕНИЯ | |
| CL2017000912A1 (es) | Anticuerpos que se unen a ccr6 y sus usos |